# A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid

> **NCT01707069** · PHASE1 · COMPLETED · sponsor: **Immunomic Therapeutics, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Allergic Rhinoconjunctivitis

## Interventions

- **BIOLOGICAL:** CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection

## Key facts

- **NCT ID:** NCT01707069
- **Lead sponsor:** Immunomic Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2013-05
- **Final completion:** 2013-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01707069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01707069, "A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01707069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*